Phase II Trial of FOLFOXIRI Plus Panitumumab as First-Line Treatment for Kras and Braf Wild-Type Metastatic Colorectal Cancer.

Trial Profile

Phase II Trial of FOLFOXIRI Plus Panitumumab as First-Line Treatment for Kras and Braf Wild-Type Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Fluorouracil; Folinic acid; Irindalone; Irinotecan; Oxaliplatin; Panitumumab
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TRIP
  • Most Recent Events

    • 07 Jun 2016 Results (n=784) of pooled analysis of 6 trials (GONO-FOLFOXIRI , FOIB, TRIP, TRIBE, MACBETH and MOMA) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 05 Oct 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 17 Mar 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2009-014556-29).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top